A groundbreaking advancement in reproductive biology has emerged from researchers at the Institut Pasteur in Paris, revealing a novel model of tiny human ovary organoids, aptly named ovaroids. This extraordinary achievement, presented at the upcoming Joint Congress of the European Society of Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) in Copenhagen, holds transformative potential for the study and treatment of a variety of disorders linked to gonadal development and function, including differences in sex development (DSDs) and infertility. These lab-grown, three-dimensional ovarian structures are derived entirely from human stem cells, offering an unprecedented human-relevant platform to investigate intricate biological processes previously inaccessible due to ethical and technical constraints.
The formation of human gonads is an exquisitely timed developmental event, occurring during embryogenesis with critical milestones set between four to six weeks post-fertilization. During this early embryonic window, the bipotential gonadal ridges differentiate into either testes or ovaries based on tightly regulated genetic and molecular cues. Studying this sex determination process has historically been fraught with complexity, hindered by its timing, ethical challenges surrounding human embryonic research, and notable species-specific differences that limit animal model extrapolation. Consequently, a complete understanding and modeling of atypical gonadal development have remained elusive, obstructing advances in diagnostics and therapeutics for DSDs.
DSDs encompass a heterogeneous group of rare conditions characterized by discordance between chromosomal sex and gonadal or anatomical sexual differentiation. Affecting approximately one in 4,500 live births, these conditions range from severe presentations detected prenatally or shortly after birth, to milder variations that may manifest at puberty or remain undiagnosed into adulthood. Despite advances in genetic sequencing over the past decade and the identification of numerous causative genes, roughly half of DSD cases with atypical gonad development still lack definitive genetic diagnoses, underscoring unmet clinical needs and the necessity for more predictive disease models.
Addressing these challenges, the research team utilized human induced pluripotent stem cells (hiPSCs), which possess the remarkable ability to differentiate into multiple cell types, to recreate key cellular constituents of the ovary. Specifically, hiPSCs were guided to become granulosa-like cells, a crucial somatic cell population responsible for nurturing maturing oocytes and supporting follicle formation. Concurrently, primordial germ cell-like cells (PGCLCs), precursors to future gametes, were generated. By co-culturing and combining these two cell populations without introducing exogenous transcription factors—which can artificially alter intrinsic genetic programs—the researchers successfully engineered complex ovarian organoids that faithfully recapitulate vital structural and functional hallmarks of human ovarian follicles.
This methodological breakthrough diverges significantly from prior models that often relied on forced expression of external transcription factors, which risk disrupting authentic developmental gene regulatory networks and limit relevance to disease modeling. According to senior author Dr. Anu Bashamboo, this endogenous differentiation strategy preserves the innate genetic programs within the cells, enhancing the fidelity and applicability of the derived populations to investigate natural ovarian development and pathology. Importantly, the functioning ovaroids exhibit critical cell-cell interactions and three-dimensional morphogenesis reflective of in vivo ovarian tissue architecture.
Complementing this advancement, collaborative work previously conducted at the Institut Pasteur and the Francis Crick Institute successfully generated hiPSC-derived somatic cells of the testis, namely Sertoli cells, which play a vital role in testicular development and are frequently implicated in DSDs. By cultivating cells carrying male sex chromosomes (XY) with genetic mutations associated with atypical testis formation, the team observed impaired formation of three-dimensional tubular structures reminiscent of seminiferous tubules, resulting in dysgenetic gonadal features analogous to human DSD phenotypes. Together, these parallel models of ovarian and testicular development establish a versatile platform for comparative analyses of gonadal biology.
The implications of these human-specific, stem cell-derived models extend far beyond basic science. They address critical limitations imposed by interspecies variation, where fundamental differences in gene regulation impede the translation of findings from animal models to humans. By enabling controlled, reproducible studies of human gonadal development, gene function, and disease mechanisms, this platform represents a transformative toolset for dissecting the molecular underpinnings of DSDs and related reproductive disorders.
Dr. Bashamboo highlights the broader significance of this research, emphasizing its capacity to bridge the divide between laboratory investigation and clinical application. The human ovaroid and testicular cell systems not only hold promise for advancing genetic diagnosis through improved modeling of previously cryptic conditions but also serve as scalable platforms for drug screening, toxicological assessment, and personalized medicine. Their utility could accelerate the development of targeted therapeutics tailored to individuals with infertility, gonadal tumors, or atypical sexual development.
Moreover, the potential for these organoids to facilitate environmental and pharmacological screenings represents a timely innovation, given increasing concerns about endocrine-disrupting chemicals and their effects on human reproductive health. By providing a physiologically relevant system, researchers can assess the impact of diverse compounds on human gonadal cells and structures in vitro, informing safer medical and environmental policies.
Looking towards the future, these stem cell-derived human gonadal models offer exciting possibilities for therapeutic interventions. With continued refinement, they may underpin regenerative strategies or novel approaches to restore or modulate gonadal function in patients affected by congenital anomalies or acquired diseases. The integration of such models within precision medicine frameworks could revolutionize fertility preservation, diagnosis, and treatment paradigms.
In summary, the development of human ovaroids from hiPSCs marks a pivotal advancement in reproductive biology research, pushing the boundaries of what can be studied and manipulated in human tissue models. It was presented at the first Joint Congress of ESPE and ESE, symbolizing a collaborative milestone in endocrine and reproductive science. With their robust and faithful recapitulation of ovarian follicular structures without exogenous genetic manipulation, these ovaroids provide a potent new avenue for unraveling developmental mysteries, improving diagnostic accuracy, and pioneering therapeutic innovations for complex gonadal conditions.
—
Subject of Research: Development of human ovary organoids (ovarioids) from induced pluripotent stem cells to model gonadal development and differences in sex development (DSDs)
Article Title: Not provided
News Publication Date: Not provided
Web References: Not provided
References: Not provided
Image Credits: European Society of Endocrinology
Keywords: Ovaries, Ovarian follicles, Reproductive system, Gonads, Testicles, Endocrine system, Endocrinology, Hormones, Cell cultures, Research methods, Laboratory procedures, Germ cells, Primordial germ cells, Differentiated cells, Pluripotent stem cells, Infertility, Ovarian tumors, Pediatrics, Diseases and disorders, Stem cell development, Sertoli cells, Stem cells
